Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.

Sibylle de GermayElodie PambrunAntoine ParienteGuillaume GrenetJulien BezinJean-Luc Faillie

Published in: Diabetes, obesity & metabolism (2024)

The expansion of indications for SGLT-2i and the broadening of the target population make it essential to assess the reasons for discontinuation and review their safety profile.

Keyphrases

health insurance
affordable care act
adverse drug
cross sectional
emergency department